# ML41253 (NCT04321330)

> A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: previously-treated advanced thymic carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04321330
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Thymic
- Interventions: Atezolizumab
- Enrollment: 34
- Primary outcome: Objective response rate (ORR)

## Indexed commentary on ML41253 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ml41253-nct04321330